AU2003219277A1 - Intracellular antibodies - Google Patents

Intracellular antibodies

Info

Publication number
AU2003219277A1
AU2003219277A1 AU2003219277A AU2003219277A AU2003219277A1 AU 2003219277 A1 AU2003219277 A1 AU 2003219277A1 AU 2003219277 A AU2003219277 A AU 2003219277A AU 2003219277 A AU2003219277 A AU 2003219277A AU 2003219277 A1 AU2003219277 A1 AU 2003219277A1
Authority
AU
Australia
Prior art keywords
intracellular antibodies
intracellular
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003219277A
Inventor
Maria Natividad LOBATO-CABALLERO
Terence Howard Rabbitts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0206043A external-priority patent/GB0206043D0/en
Priority claimed from GB0226723A external-priority patent/GB0226723D0/en
Priority claimed from GBGB0226727.6A external-priority patent/GB0226727D0/en
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of AU2003219277A1 publication Critical patent/AU2003219277A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
AU2003219277A 2002-03-14 2003-03-14 Intracellular antibodies Abandoned AU2003219277A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0206043.2 2002-03-14
GB0206043A GB0206043D0 (en) 2002-03-14 2002-03-14 Intracellular antibodies
GB0226723A GB0226723D0 (en) 2002-11-15 2002-11-15 Antibodies for in vitro use
GB0226727.6 2002-11-15
GBGB0226727.6A GB0226727D0 (en) 2002-11-15 2002-11-15 Intrabodies
GB0226723.5 2002-11-15
PCT/GB2003/001077 WO2003077945A1 (en) 2002-03-14 2003-03-14 Intracellular antibodies

Publications (1)

Publication Number Publication Date
AU2003219277A1 true AU2003219277A1 (en) 2003-09-29

Family

ID=28045958

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003219277A Abandoned AU2003219277A1 (en) 2002-03-14 2003-03-14 Intracellular antibodies

Country Status (2)

Country Link
AU (1) AU2003219277A1 (en)
WO (1) WO2003077945A1 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
GB0226723D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Antibodies for in vitro use
WO2004046188A2 (en) * 2002-11-15 2004-06-03 Medical Research Council Anti-activated ras antibodies
GB0226729D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
CN101175769A (en) 2005-03-10 2008-05-07 健泰科生物技术公司 Methods and compositions for modulating vascular integrity
US7763245B2 (en) 2005-12-15 2010-07-27 Genentech, Inc. Methods and compositions for targeting polyubiquitin
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2009087577A2 (en) * 2008-01-07 2009-07-16 Patrys Limited Barb4 target, antibody designated barb4, barb4 related antibodies, and methods of making and using same
JP5986745B2 (en) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Glycan arrays on PTFE-like aluminum-coated glass slides and related methods
AU2009308293B2 (en) 2008-10-22 2015-02-05 Genentech, Inc. Modulation of axon degeneration
GB0911215D0 (en) 2009-06-29 2009-08-12 Univ Erasmus Medical Ct Gamma globin therapy
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
CN104043126A (en) 2009-10-22 2014-09-17 霍夫曼-拉罗奇有限公司 Modulation of axon degeneration
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
SI2516465T1 (en) 2009-12-23 2016-08-31 F. Hoffmann-La Roche Ag Anti-bv8 antibodies and uses thereof
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
CA2835489C (en) 2010-05-10 2018-03-06 Chi-Huey Wong Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
AU2013306098A1 (en) 2012-08-18 2015-02-12 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
WO2014031762A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
SG10201913751RA (en) 2013-05-06 2020-03-30 Scholar Rock Inc Compositions and methods for growth factor modulation
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
EP3013347B1 (en) 2013-06-27 2019-12-11 Academia Sinica Glycan conjugates and use thereof
CN105682666B (en) 2013-09-06 2021-06-01 中央研究院 Activation of human iNKT cells using glycolipids
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
TWI687428B (en) 2014-03-27 2020-03-11 中央研究院 Reactive labelling compounds and uses thereof
CN106573971A (en) 2014-05-27 2017-04-19 中央研究院 Anti-CD20 glycoantibodies and uses thereof
EP3149161B1 (en) 2014-05-27 2021-07-28 Academia Sinica Fucosidase from bacteroides and methods using the same
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
TWI732738B (en) 2014-05-28 2021-07-11 中央研究院 Anti-tnf-alpha glycoantibodies and uses thereof
KR101602870B1 (en) 2014-07-22 2016-03-21 아주대학교산학협력단 Method for Cell-penetrating and cytosol-localizing of intact immunoglobulin antibody, and use thereof
KR101602876B1 (en) * 2014-07-22 2016-03-11 아주대학교산학협력단 Method for inhibiting activated RAS using intact immunoglobulin antibody having Cell-penetrating ability and use thereof
WO2016013871A1 (en) * 2014-07-22 2016-01-28 아주대학교산학협력단 Method for suppressing ras activated in cell by using antibody having cytoplasm penetration capacity and complete immunoglobulin form, and use for same
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
US20180072815A1 (en) 2014-10-23 2018-03-15 Singh Biotechnology, Llc Single Domain Antibodies Directed Against Intracellular Antigens
KR102207382B1 (en) * 2014-10-23 2021-01-27 싱 몰레큘러 메디신, 엘엘씨 Single domain antibodies directed against intracellular antigens
EP4183806A3 (en) 2014-11-12 2023-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
WO2016118961A1 (en) 2015-01-24 2016-07-28 Academia Sinica Cancer markers and methods of use thereof
EP3248005B1 (en) 2015-01-24 2020-12-09 Academia Sinica Novel glycan conjugates and methods of use thereof
AU2016211176B2 (en) 2015-01-30 2021-01-28 Academia Sinica; Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10330683B2 (en) 2015-02-04 2019-06-25 Genentech, Inc. Mutant smoothened and methods of using the same
WO2017041027A1 (en) 2015-09-04 2017-03-09 Obi Pharma, Inc. Glycan arrays and method of use
TWI746473B (en) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 Single domain antibodies directed against intracellular antigens
IL258768B2 (en) 2015-11-12 2023-11-01 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use
CA3019952A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
TW201808978A (en) 2016-03-08 2018-03-16 中央研究院 Methods for modular synthesis of N-glycans and arrays thereof
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR20180121786A (en) 2016-03-29 2018-11-08 오비아이 파머 인코퍼레이티드 Antibodies, pharmaceutical compositions and methods
KR20230110820A (en) 2016-04-22 2023-07-25 오비아이 파머 인코퍼레이티드 Cancer immunotherapy by immune activation or immune modulation via globo series antigens
WO2017204606A1 (en) 2016-05-27 2017-11-30 오름테라퓨틱 주식회사 Cytosol-penetrating antibody and use thereof
CN110072545A (en) 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 Immunogenicity/therapeutic glycan pool object and application thereof
KR102528998B1 (en) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 Human Antibodies, Pharmaceutical Compositions and Methods
JP7213549B2 (en) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド Antibodies, Binding Fragments, and Methods of Use
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. Glycan-interacting compounds and methods of use
JP2019535731A (en) 2016-11-21 2019-12-12 オービーアイ ファーマ，インコーポレイテッド Conjugated biological molecules, pharmaceutical compositions and methods
MA47812A (en) 2017-03-03 2021-04-14 Seagen Inc COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE
WO2019235581A1 (en) 2018-06-06 2019-12-12 国立大学法人大阪大学 METHOD FOR TREATING AND/OR PREVENTING Regnase-1-RELATED DISEASE
KR20190143826A (en) 2018-06-21 2019-12-31 오름테라퓨틱 주식회사 Cell/tissue-specific cell-penetrating antibodies
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
GB2344886B (en) * 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
EP2392596A3 (en) * 1999-12-28 2013-11-27 ESBATech, an Alcon Biomedical Research Unit LLC Intrabodies with defined framework that is stable in a reducing environment and applications thereof
JP2004538324A (en) * 2001-08-03 2004-12-24 メディカル リサーチ カウンシル Intracellular antibody

Also Published As

Publication number Publication date
WO2003077945A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
AU2003219277A1 (en) Intracellular antibodies
AU2003217912A1 (en) Antibody optimization
AU2002256895A1 (en) Anti-TRAIL-R antibodies
AU2003233465A1 (en) Structural member
AU2002335152A1 (en) Robot-phone
AU2003239197A1 (en) Novel stable anti-cd22 antibodies
AU2003280511A1 (en) Vibrator
AU2002255105A1 (en) Intracellular analysis
AU2003208685A1 (en) Podologic aid
AU2003250632A1 (en) Stereoflexography
AU2002318053A1 (en) Suplier
AU2003270055A1 (en) Neurotransmission-associated proteins
AU2002341221A1 (en) Honey-brandy
AU2002348964A1 (en) Snowbike
AU2003227916A1 (en) Kiteboard
AU2003205935A1 (en) Forming means
AU2003300785A1 (en) Carbohydrate-associated proteins
AU2002344387A1 (en) Multifunction-pillow
GB0206043D0 (en) Intracellular antibodies
GB0200928D0 (en) Intracellular antibodies
GB0203569D0 (en) Intracellular antibodies
AU2003236908A1 (en) Proteins
AU2003295760A1 (en) Organelle-associated proteins
AU2003238461A1 (en) Assays
AUPS186702A0 (en) Backpack

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase